• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UBC-CogState Partnership Short-Lived

UBC-CogState Partnership Short-Lived

March 9, 2009
CenterWatch Staff

Bethesda, Md.-based contract research organization (CRO) United BioSource Corporation (UBC) has ended its partnership with cognitive testing provider CogState—just seven months after it began.

The partnership, originally lauded as a way for UBC to offer clients computerized cognitive testing as part of the clinical research process, ended quietly, and neither company provided much detail as to why. UBC will retain its 15% ownership stake in CogState, which the company gained as part of the original partnership agreement.

“UBC and CogState mutually agreed to pursue the opportunity in the marketplace independently, rather than through a formal alliance,” said UBC president and chief financial officer Mark Clein.

UBC originally teamed with CogState, a company headquartered in Melbourne, Australia, based on a long-standing relationship between the two companies. CogState had developed computerized versions of a variety of cognitive tests, which UBC planned to offer to its clients.

“We will continue to work on existing projects together and we have great respect for their capabilities and personnel,” Clein said. At the time the UBC-CogState partner ship was announced last August, UBC said it had seen an increase in client requests for computerized cognitive testing, which standardizes results and reduces variability in clinical trials. Although the partnership has ended, Clein said, the demand for these types of services has not.

“UBC is continuing to see interest among our clients for services related to cognition, and we plan to aggressively develop both our internal capabilities as well as relevant industry relationships that will help us serve the needs of our clients,” he said.

As recently as the release of CogState’s 2008 year-end financial statement, the company listed its clinical trial business and the relationship with UBC as key focus areas for 2009.

CogState, which offers cognition testing in the areas of clinical trials, sport, health and the workplace, grew revenues from clinical drug trials by 65% in 2008, according to the company’s financial statement. The number of pharmaceutical company customers also increased 114%. Revenue from CogState Clinical Trials increased nearly $1.5 million in 2008 over 2007, with revenues of $3.55 million in 2008 compared with $2.15 million in 2007. Clinical trials represented 94% of the company’s total revenue in 2008.

CogState plans to increase resources in the United States and the UK to meet increased demand for its own technology solution, according to a UBC statement.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing